The Guest Who Cannot Eat
Abstract
In less than three years, drugs of the GLP-1 class, sold as Ozempic, Wegovy, Mounjaro and Zepbound, have become part of ordinary American life. Gallup’s National Health and Well-Being Index found in 2026 that 11 percent of American adults were taking a GLP-1 medication for weight loss, up from 3 percent two years earlier, and that self-reported adult obesity had fallen from a peak of 39.9 percent in 2022 to 36.4 percent. KFF’s tracking poll put current use, for all purposes, at about one adult in eight. Researchers at Cornell University, using purchase data from some 150,000 households, found that grocery spending fell by about 5 percent within six months of adoption, with sharper declines in snacks and sweets. Restaurant chains from Olive Garden to Shake Shack have introduced smaller portions and “GLP-1 friendly” menus. Discussion of these drugs has focused on their medical effects, their price and their consequences for the food industry.
This article reads them instead as a social and cultural event: a pharmacological intervention into the oldest of human institutions, the shared meal. Drawing on Georg Simmel and Mary Douglas on the meal, Marcel Mauss and Julian Pitt-Rivers on hospitality, Janet Siskind and Melanie Wallendorf and Eric Arnould on Thanksgiving, Mikhail Bakhtin on carnival, Erving Goffman on stigma, David Potter on American abundance and Joseph Dumit on pharmaceutical life, it makes five claims. First, GLP-1 drugs create a new figure at the American table, the guest who cannot eat, and so disturb the reciprocity on which commensality rests. Second, they restore, in pharmacological form, the ancient alternation of fast and feast: users suspend their doses to take part in holidays, reinventing a calendar of Lent and Carnival. Third, by silencing what users call “food noise”, they externalise the will, unsettling the moral economy in which thinness was earned by self-discipline and producing a new stigma of unearned thinness. Fourth, they challenge the American ethic of abundance expressed in portion size, and accompany the rise of a new food cosmology centred on protein. Fifth, because their effects depend on continued use, they inaugurate a subscription body, maintained by a permanent relationship with the pharmaceutical economy.
Keywords: commensality, hospitality, ritual, body, pharmaceuticals, abundance, stigma, United States
1. Introduction: four bites and done
For many Americans who began taking GLP-1 medications in the mid-2020s, the first discovery was not the weight they lost but the silence they found. Users describe it in remarkably similar terms. The constant inner chatter about food, what to eat next, whether to have another helping, the pull of the snack cupboard, simply stops. They call this chatter “food noise”, and its disappearance is, for many, the most striking effect of the drugs. The second discovery is social. A meal that once required a struggle of will now ends, without effort, after a few bites. As one radio feature on dining out put it in 2026, users “already know the drill: four bites in and you’re done”.
The pharmacology is well understood. GLP-1, glucagon-like peptide 1, is a gut hormone released after eating that signals satiety to the brain and slows the emptying of the stomach. The drugs mimic it, in stronger and longer-lasting form. Users feel full sooner, stay full longer and experience nausea or discomfort if they eat past that point. Clinical trials have shown weight losses of 15 to 20 percent or more of body weight with the newest agents. Originally developed for type 2 diabetes, the drugs were approved for obesity from 2021 onward, and their use has spread with extraordinary speed, through prescriptions, telehealth services, compounding pharmacies and, from 2026, partial public coverage negotiated between the federal government and the manufacturers.
The scale of adoption makes this one of the fastest changes in the American relationship to food in modern history. Gallup’s 2026 data suggest that roughly one adult in nine is currently taking a GLP-1 drug for weight loss, and one in seven has done so at some point. KFF’s figures, which include use for diabetes and heart disease, are higher still: about 18 percent of adults have taken one, and among those aged 50 to 64, current use reached 22 percent. Nearly half of adults diagnosed with diabetes were using one. Gallup reported that the national obesity rate, which had risen almost continuously for decades, had begun to fall.
The commercial consequences have attracted most attention. Studies of household purchases show measurable declines in spending on snacks, sweets, baked goods and soft drinks, and smaller declines in staples, with gains in yogurt, fresh fruit, protein bars and meat snacks. Fast-food restaurants and coffee shops have seen softer demand from users. Food companies have reformulated products and launched “GLP-1 friendly” labels; restaurant chains have shrunk portions. Financial analysts have produced estimates of the drugs’ impact on everything from snack manufacturers to airlines, whose fuel costs fall as passengers weigh less.
This article sets aside these questions, which are well covered elsewhere, to ask what anthropology can see that market analysis cannot. Food is never only nutrition. In every human society, eating is the most fundamental form of sociality: the shared meal creates and expresses relationships, marks time, defines groups and carries moral meanings. A drug that changes how much people can eat changes how they can take part in these social forms. When one American in eight carries a pharmacological limit on appetite into the dining room, the kitchen, the restaurant and the holiday table, the effects reach far beyond the scale.
The article proceeds in six steps. Section 2 analyses the disturbance GLP-1 drugs introduce into commensality and hospitality. Section 3 examines the reinvention of fast and feast. Section 4 turns to the will, “food noise” and the stigma of unearned thinness. Section 5 considers the American ethic of abundance and the new cosmology of protein. Section 6 introduces the notion of the subscription body. Section 7 concludes.
2. The guest who cannot eat
2.1 Commensality and the obligation to eat
Georg Simmel, in a short essay on “the sociology of the meal” (1910), observed a paradox. Eating is the most individual of acts, since what one person eats no other can eat; yet it is also the most universally shared, since everyone must eat. The meal transforms this physiological necessity into a social form. By eating together, at the same time, from the same dishes, according to shared rules, people turn the selfish act of consumption into a bond. Commensality, literally “sharing the table”, is among the oldest markers of kinship and alliance. Those who eat together belong together.
Mary Douglas, in her essay “Deciphering a Meal” (1972), showed that meals are structured like languages. They have a grammar, a sequence of courses and combinations that members of a culture recognise and respect, and they encode social distinctions: whom one invites to drinks, to a snack, to a full dinner, marks degrees of intimacy. To accept a meal is to accept a relationship at a certain level. To refuse it is to refuse the relationship.
This is why, in the anthropology of hospitality, the refusal of food is so charged. Marcel Mauss listed the obligation to receive alongside the obligations to give and to return: to decline a gift is to decline the bond it offers, and may be read as hostility. Julian Pitt-Rivers, in his classic essay on “the law of hospitality”, described the delicate reciprocity between host and guest. The host offers food and protection; the guest honours the host by accepting. A guest who does not eat insults the host’s generosity and casts doubt on the host’s food. In many cultures, as one physician interviewed by Fox News in late 2025 noted, it is considered rude to turn down food at family events, and relatives press guests to eat more.
American culture shares this logic. The clean plate, the second helping, the compliment to the cook expressed by eating heartily, are signs of appreciation. The host who sees guests leave food fears that it was not good. The family meal, especially at holidays, is an arena in which love is expressed through feeding and acknowledged through eating.
2.2 A new figure at the table
GLP-1 drugs introduce into this system a figure that it was not designed to accommodate: the guest who cannot eat, not because of illness visible to all, nor because of a known dietary rule such as kosher or vegetarianism, but because of an invisible pharmacological limit. This guest takes small portions, eats slowly, stops early and leaves food on the plate. To the host, the behaviour resembles that of a dissatisfied or reluctant guest. To the user, it is involuntary.
The resulting embarrassment is visible in survey data. A November 2025 survey of GLP-1 users by the online health publisher Sunlight found that, among those planning to modify their medication around Thanksgiving, 36 percent cited discomfort at having to explain their low appetite, and 31 percent cited social pressure around eating. Nearly a third of users said they might try to make it appear that they had eaten more than they actually had. A survey of diners by the restaurant platform Toast, conducted in August 2026, found that only 12 percent of GLP-1 users consistently finished their restaurant orders, while 29 percent rarely or never did.
The practice of feigned eating deserves attention. It is a small, private ritual of compliance: moving food around the plate, taking an extra serving and leaving it, accepting dessert and barely touching it. Its purpose is to preserve the appearance of reciprocity when the substance of reciprocity has become impossible. The guest honours the host’s generosity by simulating acceptance. In Goffman’s terms, it is a form of “face-work”, the effort to maintain the social self that each participant presents in an interaction. That millions of Americans now perform such face-work at their own family tables measures the depth of the disturbance.
2.3 A new etiquette
Societies respond to such disturbances by inventing new rules. The advice literature that has emerged around GLP-1 drugs is, in effect, a new etiquette in formation. Its rules are consistent. Hosts should not take reduced eating personally; it reflects the drug, not the cooking. Hosts should not pressure guests to eat or comment on how much they eat. Hosts should offer lighter options alongside traditional dishes. Above all, hosts should respect privacy: if a guest does not mention medication, it should not be raised. Users, for their part, are advised to tell close relatives in advance, to take small portions of many dishes so as to honour the meal, and to redirect attention from food to conversation.
These rules redefine hospitality. In the older model, the good host was one who fed guests abundantly and the good guest one who ate abundantly. In the emerging model, the good host is one who does not insist and the good guest one who discloses. The obligation to receive, in Mauss’s sense, is being softened into a right to decline. This change extends beyond GLP-1 users. The same etiquette, of not pressing food on guests and not commenting on plates, has long been urged by advocates for people with eating restrictions, allergies and other conditions. The drugs have given it a mass constituency.
2.4 The feeder’s loss
The disturbance is felt not only by the guest but by the person who cooks. The sociologist Marjorie DeVault, in Feeding the Family (1991), showed that the daily work of planning, preparing and serving meals, performed overwhelmingly by women, is a form of care through which family life is produced. Feeding others is not only a chore; it is a way of expressing love, maintaining relationships and constituting the household as a group. Its reward is the pleasure of those who eat.
In many American families, this role has been concentrated in particular figures: the mother who cooks the holiday meal, the grandmother whose recipes define family tradition, the aunt known for her pies. For these feeders, the guest who cannot eat represents a loss of a specific kind. The labour of days produces a meal that is barely touched. The dish that carried the family’s memory is tasted and set aside. The advice to hosts “not to take it personally” acknowledges the problem without resolving it, because in the logic of feeding, the meal is personal. It is the feeder’s gift.
The loss is compounded by the fact that the change often affects several family members at once. Survey data show that GLP-1 use is concentrated among middle-aged adults, who are, in many families, both the hosts of holiday meals and the most frequent guests. A family in which the parents and one or two adult children take the drugs may see its customary meal shrink dramatically. The feeder must then choose between cooking as before and watching food go uneaten, or adapting the menu and abandoning dishes that carry the family’s identity.
Some families are inventing new forms. Hosts report cooking smaller quantities of more dishes, so that guests can taste everything without eating much; sending more food home with guests as leftovers, which transforms the meal from a single event into a distributed gift; and shifting the emphasis of gatherings from the meal to other activities, such as games, walks or watching football together. These adaptations preserve the feeder’s role while changing its form. They suggest that commensality is resilient: it can survive the loss of appetite, but only by changing what it means to share a table.
This is the first claim of this article: GLP-1 drugs introduce into American commensality the figure of the guest who cannot eat, disturbing the reciprocity on which hospitality rests and producing both new forms of face-work, such as feigned eating, and a new etiquette in which the obligation to receive is softened into a right to decline.
3. The return of fast and feast
3.1 The lost calendar
For most of human history, eating followed a calendar. Periods of fasting alternated with periods of feasting, according to agricultural cycles and religious prescriptions. In Christian Europe, the forty days of Lent, during which meat, dairy and often eggs were forbidden, were preceded by Carnival, a period of excess that culminated in Mardi Gras, “Fat Tuesday”, and followed by the Easter feast. Islam structures the year around the month of Ramadan, with its daytime fasting and nightly breaking of the fast. Judaism has its fast days and its festivals. In each case, the fast gave meaning to the feast, and the feast to the fast.
Mikhail Bakhtin, in his study of Rabelais, described the medieval carnival as a time when the ordinary order was suspended: hierarchies inverted, bodily appetites celebrated, excess licensed. The carnival was not opposed to the ascetic order; it was its complement, a periodic release that made the discipline of Lent bearable. The two together formed a rhythm in which the body was alternately restrained and indulged.
Modern consumer societies, and the United States above all, largely abolished this rhythm. Abundance became continuous. Food was available at every hour and in every season, and the distinction between ordinary days and feast days eroded. Thanksgiving, Christmas and the Fourth of July remained occasions for special meals, but the daily diet of many Americans approached in richness what earlier generations had reserved for feasts. The fast, in its religious sense, survived mainly among the devout. Diets took its place, but diets were individual, irregular and detached from any shared calendar.
3.2 The pharmacological Lent
GLP-1 drugs reintroduce something like a permanent fast. Not a fast in the religious sense, since users eat every day, but a continuous restraint of appetite, imposed not by rule but by chemistry. The user lives, in effect, in a state of perpetual Lent: eating less, desiring less, feeling satisfied with little.
And like the faithful of earlier centuries, users have begun to organise their own carnivals. The Sunlight survey found that 40 percent of GLP-1 users planned to modify their medication routine around Thanksgiving 2025: 6 percent intended to skip a dose entirely, and 34 percent to adjust its timing or dosage. Among those planning such changes, 74 percent said they wanted to enjoy the food more. Physicians generally advise against such adjustments, warning that interrupting treatment can worsen side effects when it resumes. But the practice persists, because it answers a social need that medicine does not recognise: the need to take full part in the feast.
The structure is precisely that of Lent and Carnival, inverted in sequence. The user fasts by default and suspends the fast to feast. The suspension is timed to the communal calendar: Thanksgiving, Christmas, birthdays, weddings. The dose becomes a ritual instrument, its timing calculated so that appetite returns for the day of celebration. A new calendar of eating is emerging, shared by millions of people who do not know each other and who follow no common rule, yet who coordinate their pharmacology with the same holidays.
3.3 Thanksgiving as a test
Thanksgiving is the decisive test of this new calendar, because it is the American ritual of abundance par excellence. The anthropologist Janet Siskind described it as a “ritual of American nationality”, a domestic ceremony in which families reenact a national myth of plenty shared between Pilgrims and Native Americans. The consumer researchers Melanie Wallendorf and Eric Arnould, in a celebrated study of Thanksgiving, showed that the meal’s central meaning was the celebration of material abundance: tables laden with more food than could be eaten, leftovers that lasted for days, the ritual overeating that left participants stuffed and somnolent. The very word “stuffing” names both a dish and the condition of those who eat it.
GLP-1 drugs strike at the heart of this ritual. A guest who cannot eat abundantly cannot participate in the celebration of abundance. Market researchers at NielsenIQ found in autumn 2025 that 79 percent of GLP-1 users planned to avoid or limit certain foods and drinks at Thanksgiving, and that 27 percent of hosts aware of GLP-1 guests planned lighter menus or smaller portions. The traditional menu, turkey, stuffing, mashed potatoes, gravy, candied sweet potatoes, green bean casserole, pies, was designed for excess. Its heaviness is not incidental; it is the point.
Users’ responses suggest that the meaning of the holiday may be shifting. In the Sunlight survey, about two-thirds of GLP-1 users said they wanted future Thanksgivings to centre more on gratitude and connection than on food. One woman interviewed by the Associated Press described having dreaded the holiday for most of her life because of the guilt of overindulging, and finding on the drugs a new freedom to enjoy it. The holiday’s official meaning, as its name indicates, is thanksgiving; its practical meaning has long been feasting. A population that cannot feast may push the ritual back towards its stated purpose. The pharmacological Lent may, paradoxically, spiritualise the American feast.
This is the second claim of this article: GLP-1 drugs reinstate, in pharmacological form, the ancient alternation of fast and feast. Users live in a permanent restraint of appetite and suspend it, by adjusting their doses, to take part in communal celebrations. A new calendar of eating, coordinated with the holidays, is emerging, and the ritual of abundance at its centre is being tested and perhaps transformed.
4. The silenced will
4.1 Food noise
The phrase “food noise” did not exist in common usage before the GLP-1 era. Its rapid spread is itself a cultural fact. It names an experience that many people had lived without a word for it: the intrusive, persistent stream of thoughts about food, cravings and urges that occupy the mind. And it names it in a particular way: as noise, an external interference rather than an inner desire, something that happens to the person rather than something the person wants.
This framing has deep implications. In the dominant Western tradition, appetite has been understood as part of the self, a desire to be governed by the will. The glutton was a moral failure, someone who lacked self-control; the thin person was a moral success, someone who mastered his or her appetites. Christianity counted gluttony among the deadly sins. Protestant culture, in particular, made bodily discipline a sign of spiritual seriousness. Max Weber’s ascetic Protestant mastered the body as he mastered time and money. In American culture, the moral meaning of body weight has been especially strong, and the historian Peter Stearns, among others, has documented how the twentieth-century ideal of slenderness became a test of character.
The concept of food noise, popularised by GLP-1 users, reverses this. If the urge to eat is noise, then it is not a moral failing but a physiological malfunction, a signal that can be turned down by chemistry. The struggle of the will, which was supposed to define the moral person, is revealed to have been a struggle against a hormone. Users frequently describe the experience as liberating precisely in these terms: what they had believed to be their own weakness turned out to be a biological setting that could be adjusted.
4.2 The externalised will
The anthropology of the self helps to understand what is happening. Michel Foucault described the “technologies of the self” through which people work on their own bodies and souls: diets, exercises, confessions, regimes. Dieting has been a central technology of the modern self, demanding constant vigilance, counting and self-denial. It produced a particular kind of person: one who monitors, measures and controls.
GLP-1 drugs relocate this work. The vigilance is delegated to a molecule. The user no longer needs to resist; the drug does the resisting. In this sense, the drug externalises the will. The capacity for self-control, which moral philosophy placed at the centre of the person, is partly transferred to a pharmaceutical agent injected once a week.
This transfer has been welcomed by many users, who report relief from a lifelong struggle, and by many physicians, who see obesity as a chronic disease rather than a moral failure. But it has also provoked unease, expressed in the persistent suspicion that weight lost through medication is not quite legitimately earned. Public discourse about the drugs has been marked by accusations of “cheating”, “taking the easy way out” and “shortcuts”, and by mocking commentary on celebrities suspected of using them. The unease reveals how strongly American culture links thinness to virtue. If the drug can produce thinness without virtue, the moral meaning of thinness is threatened.
4.3 The stigma of unearned thinness
Erving Goffman distinguished between the discredited, whose stigma is visible, and the discreditable, whose stigma can be concealed but may be revealed. Obesity has long placed people in the first category: a visible condition that, in American culture, carried a heavy moral stigma. GLP-1 drugs move many users into the second. Their weight loss is visible, but its cause is not. They become discreditable: their new body may be read as an achievement of will, but they know that it is, in part, the effect of a drug, and they fear the revelation.
This explains the central place of secrecy and disclosure in the new etiquette described above. Advice to hosts not to raise a guest’s medication, advice to users about whether and how to tell relatives, the debates on social media about celebrities who “admit” to using the drugs, all revolve around the management of a discreditable secret. The verb “admit” is revealing: one admits to a fault, not to a treatment.
The stigma extends to commercial practice. Research by the consumer-insight firm Curion found what it called a “GLP-1 menu paradox”: consumers wanted smaller, protein-rich options, but more than a third rejected menu items explicitly labelled “GLP-1 friendly”, even though they wanted the food itself. Restaurants responded by framing their new offerings in neutral terms, such as “lighter portions” or “high protein”, rather than naming the drug. The Darden executive who introduced Olive Garden’s smaller portions explained that the new menu simply “happens to benefit” consumers on GLP-1 medications. The label is avoided because it would mark the customer as discreditable.
There is a further twist. As the drugs spread, a counter-stigma has appeared: the suspicion that any thin person may be using them. Natural thinness, or thinness achieved through diet and exercise, becomes harder to display as an achievement when it might be pharmacological. The moral currency of the slender body, accumulated over a century of American diet culture, is being devalued. In time, this may weaken the association between body size and virtue altogether, a change that critics of weight stigma have long sought, though by an unexpected route.
This is the third claim of this article: by silencing “food noise”, GLP-1 drugs externalise the will and unsettle the moral economy in which thinness was earned by self-discipline. They turn many users into bearers of a discreditable secret, produce a new stigma of unearned thinness, and may ultimately devalue the moral currency of the slender body in American culture.
5. The end of abundance on the plate
5.1 A people of plenty
In 1954 the historian David Potter published People of Plenty, arguing that abundance was the key to American national character. Where other nations had been shaped by scarcity, Americans had been shaped by an unprecedented availability of land, resources and goods. Abundance, Potter argued, explained American optimism, American mobility, American democracy and the American faith in progress. It also shaped everyday habits, from the size of houses to the size of cars to the size of meals.
Portion size is one of the most concrete expressions of this ethic. The American restaurant meal has long been, by international standards, enormous. The “all you can eat” buffet, the “bottomless” drink, the “supersized” fast-food menu, the steak that covers the plate and the leftovers carried home in a box, are not incidental features of American food culture. They express a moral equation between quantity and value, and between generosity and size. The good restaurant gives you more than you can eat. The good host does the same. A meal that leaves you hungry is a meal that cheated you.
This equation was sustained by economics. Food was cheap relative to labour and rent, so restaurants could compete on quantity without ruinous costs. Large portions signalled value to customers who measured their spending against the volume received. And the cultural value of abundance gave large portions a symbolic meaning beyond price: they were a sign of America itself.
5.2 Shrinking plates
GLP-1 drugs confront this equation with a large population for whom more is not better, because they physically cannot eat more. The response of the restaurant industry has been rapid. Smoothie King launched what it described as the first dedicated GLP-1 menu in October 2024. Chipotle added labelled items to a high-protein menu in December 2025. Shake Shack introduced a “Good Fit” menu with lettuce-wrapped burgers. Olive Garden, a chain built on bottomless breadsticks and generous pasta, rolled out a “Lighter Portions” section nationwide in January 2026. The Cheesecake Factory, famous for oversized servings, added smaller “Bites and Bowls”. TGI Fridays tested a menu called “Eat Like a Kid”. Industry surveys suggest that a substantial share of operators are considering or already offering dishes aimed at GLP-1 users, and that users themselves overwhelmingly want smaller versions of regular dishes: in the Toast survey, 87 percent said they would order them if offered, and 21 percent reported ordering more often from children’s menus.
The adoption of children’s portions by adults is a small but telling detail. In the cultural grammar of the American restaurant, the children’s menu marks a category of eater not yet entitled to the full adult portion. Adults ordering from it, or chains naming a menu “Eat Like a Kid”, invert this grammar. The full adult portion, once the sign of adult appetite and adult entitlement, becomes an excess that adults avoid.
The change is not confined to drug users. Industry observers note that the trend towards smaller portions extends to consumers who are not taking GLP-1 medications, driven also by price pressures and concern about waste. The Curion research found that most consumers who said they would never take the drugs still wanted the same lighter options. In this sense, GLP-1 users may be acting as a vanguard, legitimising a shift in norms that a broader public was ready to accept. Once smaller portions are normal for a large minority, they become available and acceptable for everyone.
5.3 The cosmology of protein
As portions shrink, their composition changes. The dominant nutritional advice for GLP-1 users is to prioritise protein, both to preserve muscle mass during weight loss and because protein is more satiating. The new menus are organised around protein counts, displayed prominently: a bowl with so many grams, a drink with so many more. Protein bars, protein shakes, protein-enriched coffee drinks and protein snacks have proliferated in American retail, and purchase data show GLP-1 users buying more of them.
Mary Douglas taught that systems of food rules are systems of classification that separate the pure from the impure. In Purity and Danger (1966), she showed that the dietary laws of Leviticus were not arbitrary hygiene but expressions of a cosmological order. Contemporary American nutrition culture has its own cosmology, and in the GLP-1 era it is crystallising around a simple opposition: protein, which is pure, strengthening and good; and sugar and refined carbohydrates, which are dangerous, weakening and bad. The display of protein grams on menus functions like a certificate of purity. The “high protein” label, unregulated and sometimes applied to products of dubious nutritional value, works less as information than as a sign of moral and physical safety.
This cosmology did not originate with GLP-1 drugs. Its roots lie in decades of diet culture, from Atkins to the “paleo” and “keto” movements, and in the fitness culture that made protein the nutrient of the muscular body. But the drugs have given it a medical authority and a mass market. The American plate of the late 2020s is becoming smaller, denser and more protein-focused, and its moral language has changed accordingly: from “more” to “better”, from quantity to composition, from abundance to optimisation.
This is the fourth claim of this article: GLP-1 drugs challenge the American ethic of abundance as expressed in portion size, prompting a rapid reduction of restaurant servings that inverts the old equation of quantity and value, and they consolidate a food cosmology in which protein is the pure nutrient. The people of plenty is learning, at least at the table, the virtues of sufficiency.
6. The subscription body
6.1 A drug for life
GLP-1 drugs have a characteristic that distinguishes them from most earlier weight-loss interventions: their effects depend on continued use. Clinical studies have shown that patients who stop treatment typically regain a large part of the weight they lost within a year or two, as appetite returns. Physicians increasingly describe the drugs as long-term or indefinite treatments for a chronic condition, comparable to medications for blood pressure or cholesterol. For many users, the drug is not a course of treatment but a permanent condition of their new body.
The anthropologist Joseph Dumit, in Drugs for Life (2012), analysed how the pharmaceutical industry and contemporary medicine have redefined health as a state of chronic risk to be managed by continuous medication. Under this model, more and more people are defined as needing drugs not to cure a disease but to reduce the risk of one, and for life. Dumit showed that the growth of pharmaceutical markets depends less on curing illness than on expanding the number of people taking drugs indefinitely.
GLP-1 drugs fit this model with unusual clarity, and they extend it to the most intimate aspect of embodied life: appetite. The user’s body, in its new shape, is maintained by a weekly injection or, with newer oral formulations, a daily pill. Stopping the drug means losing the body. The body has become, in a sense, a subscription: a state that persists only as long as the payments continue.
6.2 Paying for the body
The language of subscription is not merely metaphorical. American consumers have become accustomed to subscription models for software, entertainment, food delivery and much else: recurring payments for continued access, with access ending when payments stop. Many GLP-1 users obtain their drugs through telehealth companies that operate precisely on this model, charging a monthly fee that bundles consultation and medication. The relationship between user and drug is mediated by a recurring transaction.
The costs are substantial and unevenly borne. KFF found that about a quarter of GLP-1 users paid the whole cost themselves, and that many found the drugs difficult to afford. List prices for branded drugs have run to many hundreds of dollars a month, although federal agreements with the manufacturers announced in late 2025, and the growth of direct-to-consumer and compounded options, have lowered prices for some. Gallup found that compounded versions accounted for nearly a fifth of current use. Coverage varies widely among private insurers, and public coverage for obesity remains partial.
The result is that the new body is distributed according to the ability to sustain the subscription. Bourdieu showed that the body is a site of class distinction: the slim, toned body of the upper middle class and the heavier body of the working class are not natural differences but products of different conditions of life, tastes and resources. Thinness has long been associated with affluence in Western societies. GLP-1 drugs could, in principle, weaken this association, by making thinness available to anyone who can obtain the drug. In practice, they risk reinforcing it, by making the thin body a product that must be purchased continuously. Those who can pay keep their new bodies; those whose coverage lapses or whose finances tighten lose them.
6.3 A new relation to the self
The subscription body also changes the relation between people and their own bodies. In the older model, the body was something one had and shaped through effort: it was one’s own, for better or worse. In the subscription model, the body is something one maintains through a relationship with an external provider. Its shape depends on a supply chain, a prescription, an insurance decision and a pharmaceutical company’s pricing strategy.
This is not entirely new. Many people already depend on medications to maintain their health. What is new is the scale, the visibility and the domain. Millions of Americans now experience their weight, appetite and appearance as the result of a pharmaceutical relationship. Their sense of who they are, at the table and in the mirror, is tied to a product. The shortages of 2023 and 2024, when demand outstripped supply and users struggled to fill prescriptions, gave a foretaste of the anxiety this produces: the fear that the body might be taken away.
This is the fifth claim of this article: because the effects of GLP-1 drugs depend on continued use, they inaugurate a subscription body, maintained through a permanent relationship with the pharmaceutical economy. This body is distributed according to the ability to pay, and it transforms the relation between people and their own appetites from one of struggle into one of supply.
7. Conclusion: a society relearning how to eat together
GLP-1 drugs are usually discussed as a medical breakthrough, a public-health opportunity, a commercial disruption or a fiscal challenge. They are all of these. But they are also a social experiment of unprecedented scale: the introduction into a national food culture of a large population whose appetite has been pharmacologically reset.
The anthropological perspective reveals the depth of this experiment. At the family table, the drugs disturb the reciprocity of hospitality and produce a new etiquette of non-insistence and discretion. In the calendar, they revive the rhythm of fast and feast, as users suspend their doses to celebrate. In the moral domain, they externalise the will and unsettle the meaning of thinness. In the restaurant, they shrink the American plate and challenge an ethic of abundance as old as the republic. In the economy of the body, they create a subscription that binds users to a pharmaceutical supply.
None of these changes is complete, and some may reverse. Newer drugs may have different effects; prices may fall; cultural resistance may grow. But the direction is clear. A society that defined itself by abundance is learning, through chemistry, the uses of sufficiency. A culture that celebrated the stuffed guest is learning to accommodate the guest who stops after four bites. And a nation that treated body weight as a test of character is discovering that character may have been, in part, a hormone.
Whether this produces a healthier and more tolerant food culture, or a more anxious and stratified one, will depend on choices yet to be made: about access and price, about the stigma attached to medication, and about the meaning Americans give to their shared meals. The table has always been the place where societies reproduce themselves. What happens there in the coming years will say much about the kind of society the United States is becoming.
References
Bakhtin, Mikhail. 1984 [1965]. Rabelais and His World. Bloomington: Indiana University Press.
Bourdieu, Pierre. 1984. Distinction: A Social Critique of the Judgement of Taste. Cambridge, MA: Harvard University Press.
DeVault, Marjorie L. 1991. Feeding the Family: The Social Organization of Caring as Gendered Work. Chicago: University of Chicago Press.
Douglas, Mary. 1966. Purity and Danger: An Analysis of Concepts of Pollution and Taboo. London: Routledge and Kegan Paul.
Douglas, Mary. 1972. “Deciphering a Meal.” Daedalus 101 (1): 61-81.
Dumit, Joseph. 2012. Drugs for Life: How Pharmaceutical Companies Define Our Health. Durham: Duke University Press.
Foucault, Michel. 1988. “Technologies of the Self.” In Technologies of the Self: A Seminar with Michel Foucault, edited by Luther H. Martin, Huck Gutman and Patrick H. Hutton, 16-49. Amherst: University of Massachusetts Press.
Gallup. 2026. National Health and Well-Being Index: GLP-1 Use and Obesity. Washington, DC: Gallup.
Goffman, Erving. 1963. Stigma: Notes on the Management of Spoiled Identity. Englewood Cliffs, NJ: Prentice-Hall.
Goffman, Erving. 1967. Interaction Ritual: Essays on Face-to-Face Behavior. New York: Anchor.
KFF. 2025. KFF Health Tracking Poll: The Public’s Use and Views of GLP-1 Drugs. San Francisco: KFF.
Mauss, Marcel. 1990 [1925]. The Gift: The Form and Reason for Exchange in Archaic Societies. London: Routledge.
Pitt-Rivers, Julian. 1977. “The Law of Hospitality.” In The Fate of Shechem, or the Politics of Sex: Essays in the Anthropology of the Mediterranean, 94-112. Cambridge: Cambridge University Press.
Potter, David M. 1954. People of Plenty: Economic Abundance and the American Character. Chicago: University of Chicago Press.
Simmel, Georg. 1997 [1910]. “Sociology of the Meal.” In Simmel on Culture, edited by David Frisby and Mike Featherstone, 130-135. London: Sage.
Siskind, Janet. 1992. “The Invention of Thanksgiving: A Ritual of American Nationality.” Critique of Anthropology 12 (2): 167-191.
Stearns, Peter N. 1997. Fat History: Bodies and Beauty in the Modern West. New York: New York University Press.
Wallendorf, Melanie and Eric J. Arnould. 1991. “‘We Gather Together’: Consumption Rituals of Thanksgiving Day.” Journal of Consumer Research 18 (1): 13-31.
Weber, Max. 2001 [1905]. The Protestant Ethic and the Spirit of Capitalism. London: Routledge.
Driss EFFINA, PhD
Independent Researcher, Global Strategy Files
The opening pages of our four country reports: United States, United Kingdom, Japan and China. A free PDF, sent to your inbox.
You will also receive occasional analysis from Global Strategy Files. Unsubscribe in one click, at any time.